Testosterone Does Not Increase Triglycerides at Physiologic Replacement Doses
Testosterone replacement therapy at physiologic doses does not increase triglyceride levels and may actually reduce them in hypogonadal men. 1
Evidence from Guidelines
The most authoritative evidence comes from the New England Journal of Medicine guideline on testosterone replacement therapy, which specifically examined lipid effects across multiple studies. In a dose-ranging study of 61 men receiving testosterone enanthate (25-600 mg weekly for 20 weeks), there were no changes in triglyceride levels at any physiologic dose of testosterone 1. Only supraphysiologic doses (600 mg weekly, well above replacement levels) affected lipids, and even then, the primary change was HDL reduction, not triglyceride elevation.
A meta-analysis by Whitsel et al. examining intramuscular testosterone esters in hypogonadal men found that triglyceride levels were essentially unchanged across studies 1. The guideline concludes that testosterone replacement therapy within the physiologic range has a neutral effect on lipid profiles 1.
Important Distinction: Dose Matters
The key distinction is between:
- Physiologic replacement doses: Used for treating hypogonadism (typically 50-125 mg testosterone enanthate weekly or equivalent transdermal doses) - these do NOT increase triglycerides 1
- Supraphysiologic/abuse doses: Used by bodybuilders or athletes (>300 mg weekly) - these may affect lipids differently 2
Clinical Evidence Shows Potential Benefit
Recent research actually suggests testosterone may reduce triglycerides in certain populations:
- A 2014 meta-analysis in hypogonadal men with type 2 diabetes found testosterone reduced triglyceride levels (mean difference: -0.35 mmol/L) 3
- A long-term registry study of 255 men showed triglycerides decreased from 3.14 to 2.16 mmol/L over 60 months of testosterone therapy 4
- Another 2014 study found triglycerides decreased by -0.40 mmol/L in older men with abdominal obesity 5
Route of Administration
Both intramuscular and transdermal testosterone administration show minimal effects on triglycerides:
- A 36-month study of 108 men on transdermal testosterone found no significant difference in lipid levels 1
- A 24-week multicenter study comparing transdermal and intramuscular routes found no significant lipid differences between groups 1
Current Guideline Recommendations
The 2020 Endocrine Society lipid management guideline explicitly states: "In patients with low testosterone levels, we suggest testosterone therapy as symptomatically indicated, and not as an approach to improve dyslipidemia" 2. This recommendation (grade 2⊕⊕OO) indicates testosterone is neutral for lipids—neither beneficial nor harmful enough to guide treatment decisions.
The 2018 Endocrine Society testosterone therapy guideline similarly recommends against using testosterone to improve glycemic control in type 2 diabetes 6, reinforcing that metabolic effects, while potentially favorable, are not the primary indication.
Common Pitfall to Avoid
Do not confuse anabolic steroid abuse with testosterone replacement therapy. The guideline specifically notes that supraphysiologic doses of oral nonaromatizable androgenic steroids lower HDL levels 1. The 2020 guideline advises investigating anabolic steroid abuse in patients with very low HDL (<30 mg/dL) without hypertriglyceridemia 2.
Monitoring Recommendation
While testosterone doesn't increase triglycerides, the FDA label for testosterone cypionate recommends checking serum cholesterol periodically during long-term androgen administration 7. This is standard monitoring practice, not because of expected triglyceride elevation, but for comprehensive cardiovascular risk assessment.
Gender-Affirming Hormone Therapy Context
In transgender individuals receiving masculinizing therapy, the picture differs slightly. A 2024 meta-analysis found testosterone in transmasculine individuals was associated with triglyceride increases of 30.7 mg/dL 8, and a 2023 study showed 26-37% increases in mean triglyceride levels 9. However, these studies often involved younger, otherwise healthy individuals without baseline hypogonadism, representing a different clinical context than replacement therapy in hypogonadal men.